ClinicalTrials.gg
CompletedNCT05520762HARTUpdated Oct 20, 2026

Hospital Airway Resuscitation Trial

An interventional study of A strategy of first choice supraglottic airway and A strategy of first choice endotracheal intubation in Cardiac Arrest and Respiratory Failure, sponsored by Montefiore Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Montefiore Medical Center · Not applicable, Interventional, and Treatment

How we know

Updated Oct 20, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,083
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 171 studies in Heart Arrest with a site in United States — 40 open to participants now, 45 under way, 2 of them phase 3. Heart Arrest · United States.

Enrollment
24th of 117
1,083 · median 72
Started
2023
with 9 others
No phase
67 of 171
15 open now
Registered
127th of 171
by date

Among the 171 studies in Heart Arrest with a site in United States, this one is the 24th largest by enrollment of the 117 interventional ones that give a count, is one of 10 that started in 2023, is one of 67 with no phase, and was the 127th registered.

Heart Arrest

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

40 of the 171 studies in Heart Arrest with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 171 studies in Heart Arrest with a site in United States, or all of them as a file.
02

Study summary

The Hospital Airway Resuscitation Trial (HART) is a cluster-randomized, pragmatic trial of advanced airway management with a strategy of first choice supraglottic airway vs. first choice endotracheal intubation during in-hospital cardiac arrest.

Read the detailed description

In-hospital cardiac arrest occurs in nearly 300,000 hospitalized patients in the United States each year and results in substantial morbidity and mortality. Nevertheless, the evidence base guiding the management of in-hospital cardiac arrest is quite limited and society guidelines generally extrapolate data from the out-of-hospital cardiac setting to inform in-hospital arrest care. As compared to out-of-hospital arrest, however, in-hospital arrest victims tend to have more medical comorbidities, have a witnessed arrest, and be attended to by professional first responders with advanced monitoring and treatment capabilities. Advanced airway management is a key element of cardiac arrest resuscitation. The American Heart Association makes broad recommendations regarding airway management during in-hospital cardiac, supporting endotracheal intubation (a complex procedure requiring placement of an endotracheal tube through the vocal cords) and supraglottic airway placement (a less complex advanced airway modality wherein the device is placed blindly in the supraglottic space). Data from the out-of-hospital cardiac arrest setting has found that a supraglottic airway strategy may be similar or superior to a more complex endotracheal intubation strategy. There is no randomized data to guide practice in the in-hospital setting. We intend to address this knowledge gap by performing the Hospital Airway Resuscitation Trial (HART)-a highly-innovative, pragmatic cluster-randomized trial leveraging the unified clinical and research infrastructure within the Montefiore HealthSystem (New York City) to conduct a first-of-its-kind in-hospital arrest trial in a highly diverse patient population. Specifically, a mixture of academic and community hospitals within the MontefioreHealth system will be randomized to either a strategy of first-choice endotracheal intubation or a strategy of first choice supraglottic airway, with crossovers occurring at regular intervals. Key outcomes for the trial will include return of spontaneous circulation, alive-and-ventilator-free days, and hospital survival.

03

Conditions studied

  • Cardiac Arrest
  • Respiratory Failure

Keywords

  • Cardiac Arrest
  • Emergency Airway Management
  • In-hospital Cardiac Arrest
  • Endotracheal Intubation
  • Supraglottic Airway
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult aged >=18 years
  2. Admitted to the hospital for any condition
  3. Suffered in-hospital cardiac arrest (loss of pulse and ≥2 minutes of chest compressions)
  4. Need for assisted ventilation (defined by initiation of bag-mask-ventilation or other supported ventilation)

Exclusion criteria

Exclusion Criteria:

  1. Cardiac arrest in the Operating Room or other area not responded to by Critical Care/Emergency Department (ED) teams.
  2. Cardiac arrest in which an invasive airway (i.e. endotracheal tube, tracheostomy tube) is already in place
  3. Patients with Do Not Resuscitate or Do Not Intubate orders
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
1,083 participants (actual)

Study arms

  • Experimental
    First choice supraglottic airway device, Then First choice endotracheal intubation

    A strategy of 'first choice' supraglottic airway during cardiac arrest. Clinicians can deviate to the airway management approach of their choice if deemed to be in the best interest of the patient. As part of a cluster-randomized design, hospitals (4 in the system) will be assigned to one arm for a month and then cross-over to the other arm.

    Procedure: A strategy of first choice supraglottic airway · Procedure: A strategy of first choice endotracheal intubation

  • Active comparator
    First choice endotracheal intubation, Then First choice supraglottic airway

    A strategy of 'first choice' endotracheal intubation during cardiac arrest. Clinicians can deviate to the airway management approach of their choice if deemed to be in the best interest of the patient. As part of a cluster-randomized design, hospitals (4 in the system) will be assigned to one arm for a month and then cross-over to the other arm.

    Procedure: A strategy of first choice supraglottic airway · Procedure: A strategy of first choice endotracheal intubation

Interventions

  • ProcedureA strategy of first choice supraglottic airway

    See description in Arms section

  • ProcedureA strategy of first choice endotracheal intubation

    See description in Arms section

06

What researchers measure

Primary outcomes

  1. Alive-and-ventilator free days

    The number of days a patient is alive and breathing independently of invasive mechanical ventilation will be summarized by study arm using basic descriptive statistics. A patient who leaves the hospital alive and is not discharged to a hospice setting, will be considered to have lived to 28-days. A patient discharged to a hospice facility will be assessed as having died on the day of hospital discharge. A patient who is discharged on invasive mechanical ventilation, will be assumed to have remained on invasive mechanical ventilation through 28-days.

    Time frame: From cardiac arrest until 28-days after cardiac arrest

Secondary outcomes

  1. Return of spontaneous circulation (ROSC)

    ROSC will be assessed. ROSC is defined as having ≥20 minutes of continuous spontaneous circulation without chest compressions. Rates of ROSC will be summarized by study arm using basic descriptive statistics.

    Time frame: Onset of in-hospital cardiac arrest event until either ROSC or death up to 24 hours

  2. 72 hour survival

    Survival to 72 hour after in-hospital cardiac arrest (IHCA) event will be summarized by study arm using basic descriptive statistics.

    Time frame: From IHCA event until 72 hours after IHCA event

  3. 28 day survival

    Survival to 28 days after cardiac IHCA event will be summarized by study arm using basic descriptive statistics.

    Time frame: From IHCA event until 28 days after IHCA event

  4. Functional Outcome at Discharge

    Functional Outcome at Discharge will be measured using the modified Rankin Scale (mRS). The mRS is a clinical tool that measures the patient's function disability (ability to perform daily living activities). The mRS is based on a 7-point scale ranging from 0 ("No symptoms at all") to 6 ("Death") such that higher scores are associated with increased functional disability. Scores at discharge can be used as a proxy to help identify patients who may require closer follow-up given the difficulty in obtaining long-term follow-up. mRS scores will be dichotomized to identify all patients with mRS\>3 and summarized by study arm.

    Time frame: Time of hospital discharge

  5. Survival to hospital discharge

    Survival to hospital discharge, truncated at 60 days for the purposes of this outcome, will be summarized by study arm using basic descriptive statistics.

    Time frame: From IHCA event until 60 days after cardiac arrest

Other outcomes

  1. Prolonged pauses

    The number of prolonged pauses, defined as pauses lasting \>5 seconds in duration, in chest compressions during active Cardiopulmonary Resuscitation (CPR) will be determined. Prolonged pauses will be summarized by study arm using basic descriptive statistics.

    Time frame: From start of chest compressions during cardiac arrest until ROSC or death up to 24-hours

  2. Rate of ventilator-associated pneumonia (VAP)

    Rate of VAP in the 7 days after cardiac arrest. VAP defined as new pneumonia while receiving mechanical ventilation after cardiac arrest. New pneumonia will be defined by 1) new pulmonary infiltrate on chest imaging 2) either new/worsening fever or leukocytosis 3) either change in sputum composition/frequency or worsening gas exchange or new/worsening cough or dyspnea. Rates of VAP will be summarized by study arm using basic descriptive statistics.

    Time frame: Cardiac arrest until 7 days after cardiac arrest

  3. Chest compression fraction

    Percentage of total cardiac arrest time during which chest compressions are being performed will be determined. Results will be summarized by study arm using basic descriptive statistics.

    Time frame: From start of chest compressions during cardiac arrest until ROSC or death up to 24-hours

  4. Time to advanced airway

    Time from initiation of chest compressions to advanced airway placement

    Time frame: Time from initiation of chest compressions to advanced airway placement

  5. Longest Overall Pause in Chest Compression

    The duration of the longest overall pause in chest compression will be determined. This interval will be summarized by arm using basic descriptive statistics. It is hypothesized that supraglottic airway (SGA) placement will result in chest compression pauses of shorter durations.

    Time frame: At time of cardiac arrest, less than one day

  6. Number of Overall Pauses in Chest Compression

    The number of overall pauses in chest compression, greater than 5 seconds in duration, will be summarized by arm using basic descriptive statistics. It is hypothesized that SGA placement will result in fewer chest compression pauses

    Time frame: At time of cardiac arrest, less than one day

  7. Time to epinephrine

    Time from initiation of chest compressions to first epinephrine for cardiac arrest with initial non-shockable rhythm

    Time frame: Time from initiation of chest compressions to first epinephrine for cardiac arrest with initial non-shockable rhythm

07

Study locations

1 site
  • Montefiore Medical Center
    New York, New York 10467, United States
08

References and documents

Publications

  • Holmberg MJ, Ross CE, Fitzmaurice GM, Chan PS, Duval-Arnould J, Grossestreuer AV, Yankama T, Donnino MW, Andersen LW; American Heart Association's Get With The Guidelines-Resuscitation Investigators. Annual Incidence of Adult and Pediatric In-Hospital Cardiac Arrest in the United States. Circ Cardiovasc Qual Outcomes. 2019 Jul 9;12(7):e005580. PubMed 31545574 ↗
  • Coute RA, Panchal AR, Mader TJ, Neumar RW. National Institutes of Health-Funded Cardiac Arrest Research: A 10-Year Trend Analysis. J Am Heart Assoc. 2017 Jul 12;6(7):e005239. doi: 10.1161/JAHA.116.005239. PubMed 28701308 ↗
  • Sinha SS, Sukul D, Lazarus JJ, Polavarapu V, Chan PS, Neumar RW, Nallamothu BK. Identifying Important Gaps in Randomized Controlled Trials of Adult Cardiac Arrest Treatments: A Systematic Review of the Published Literature. Circ Cardiovasc Qual Outcomes. 2016 Nov;9(6):749-756. doi: 10.1161/CIRCOUTCOMES.116.002916. Epub 2016 Oct 18. PubMed 27756794 ↗
  • Wang HE, Kupas DF, Greenwood MJ, Pinchalk ME, Mullins T, Gluckman W, Sweeney TA, Hostler D. An algorithmic approach to prehospital airway management. Prehosp Emerg Care. 2005 Apr-Jun;9(2):145-55. doi: 10.1080/10903120590924618. PubMed 16036838 ↗
  • Panchal AR, Bartos JA, Cabanas JG, Donnino MW, Drennan IR, Hirsch KG, Kudenchuk PJ, Kurz MC, Lavonas EJ, Morley PT, O'Neil BJ, Peberdy MA, Rittenberger JC, Rodriguez AJ, Sawyer KN, Berg KM; Adult Basic and Advanced Life Support Writing Group. Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2020 Oct 20;142(16_suppl_2):S366-S468. doi: 10.1161/CIR.0000000000000916. Epub 2020 Oct 21. No abstract available. PubMed 33081529 ↗
  • Bradley SM, Zhou Y, Ramachandran SK, Engoren M, Donnino M, Girotra S. Retrospective cohort study of hospital variation in airway management during in-hospital cardiac arrest and the association with patient survival: insights from Get With The Guidelines-Resuscitation. Crit Care. 2019 May 6;23(1):158. doi: 10.1186/s13054-019-2426-5. PubMed 31060580 ↗
  • Wang HE, Schmicker RH, Daya MR, Stephens SW, Idris AH, Carlson JN, Colella MR, Herren H, Hansen M, Richmond NJ, Puyana JCJ, Aufderheide TP, Gray RE, Gray PC, Verkest M, Owens PC, Brienza AM, Sternig KJ, May SJ, Sopko GR, Weisfeldt ML, Nichol G. Effect of a Strategy of Initial Laryngeal Tube Insertion vs Endotracheal Intubation on 72-Hour Survival in Adults With Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial. JAMA. 2018 Aug 28;320(8):769-778. doi: 10.1001/jama.2018.7044. PubMed 30167699 ↗
  • Moskowitz A, Holmberg MJ, Donnino MW, Berg KM. In-hospital cardiac arrest: are we overlooking a key distinction? Curr Opin Crit Care. 2018 Jun;24(3):151-157. doi: 10.1097/MCC.0000000000000505. PubMed 29688939 ↗
  • Apfelbaum JL, Hagberg CA, Connis RT, Abdelmalak BB, Agarkar M, Dutton RP, Fiadjoe JE, Greif R, Klock PA, Mercier D, Myatra SN, O'Sullivan EP, Rosenblatt WH, Sorbello M, Tung A. 2022 American Society of Anesthesiologists Practice Guidelines for Management of the Difficult Airway. Anesthesiology. 2022 Jan 1;136(1):31-81. doi: 10.1097/ALN.0000000000004002. PubMed 34762729 ↗
  • Yehya N, Harhay MO, Curley MAQ, Schoenfeld DA, Reeder RW. Reappraisal of Ventilator-Free Days in Critical Care Research. Am J Respir Crit Care Med. 2019 Oct 1;200(7):828-836. doi: 10.1164/rccm.201810-2050CP. PubMed 31034248 ↗
  • Schoenfeld DA, Bernard GR; ARDS Network. Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med. 2002 Aug;30(8):1772-7. doi: 10.1097/00003246-200208000-00016. PubMed 12163791 ↗
  • Witten L, Gardner R, Holmberg MJ, Wiberg S, Moskowitz A, Mehta S, Grossestreuer AV, Yankama T, Donnino MW, Berg KM. Reasons for death in patients successfully resuscitated from out-of-hospital and in-hospital cardiac arrest. Resuscitation. 2019 Mar;136:93-99. doi: 10.1016/j.resuscitation.2019.01.031. Epub 2019 Jan 30. PubMed 30710595 ↗
  • Haywood K, Whitehead L, Nadkarni VM, Achana F, Beesems S, Bottiger BW, Brooks A, Castren M, Ong MEH, Hazinski MF, Koster RW, Lilja G, Long J, Monsieurs KG, Morley PT, Morrison L, Nichol G, Oriolo V, Saposnik G, Smyth M, Spearpoint K, Williams B, Perkins GD; COSCA Collaborators. COSCA (Core Outcome Set for Cardiac Arrest) in Adults: An Advisory Statement From the International Liaison Committee on Resuscitation. Resuscitation. 2018 Jun;127:147-163. doi: 10.1016/j.resuscitation.2018.03.022. Epub 2018 Apr 26. PubMed 29706235 ↗
  • Hemming K, Kasza J, Hooper R, Forbes A, Taljaard M. A tutorial on sample size calculation for multiple-period cluster randomized parallel, cross-over and stepped-wedge trials using the Shiny CRT Calculator. Int J Epidemiol. 2020 Jun 1;49(3):979-995. doi: 10.1093/ije/dyz237. PubMed 32087011 ↗
  • Sevransky JE, Rothman RE, Hager DN, Bernard GR, Brown SM, Buchman TG, Busse LW, Coopersmith CM, DeWilde C, Ely EW, Eyzaguirre LM, Fowler AA, Gaieski DF, Gong MN, Hall A, Hinson JS, Hooper MH, Kelen GD, Khan A, Levine MA, Lewis RJ, Lindsell CJ, Marlin JS, McGlothlin A, Moore BL, Nugent KL, Nwosu S, Polito CC, Rice TW, Ricketts EP, Rudolph CC, Sanfilippo F, Viele K, Martin GS, Wright DW; VICTAS Investigators. Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis: The VICTAS Randomized Clinical Trial. JAMA. 2021 Feb 23;325(8):742-750. doi: 10.1001/jama.2020.24505. PubMed 33620405 ↗
  • Nichol G, Brown SP, Perkins GD, Kim F, Sterz F, Broeckel Elrod JA, Mentzelopoulos S, Lyon R, Arabi Y, Castren M, Larsen P, Valenzuela T, Graesner JT, Youngquist S, Khunkhlai N, Wang HE, Ondrej F, Sastrias JM, Barasa A, Sayre MR. What change in outcomes after cardiac arrest is necessary to change practice? Results of an international survey. Resuscitation. 2016 Oct;107:115-20. doi: 10.1016/j.resuscitation.2016.08.004. Epub 2016 Aug 23. PubMed 27565860 ↗
  • Moskowitz A, Andrea L, Shiloh AL, Cardasis J, Carty C, Kim M, Xie X, McAllen S, Esses D, Lutz C, Takematsu M, Romero J, Schimmrich K, Fein DG, Dodi AE, Rednor S, Bangar M, Mohamed A, Eisen LA, Wang HE, Donnino MW, Gong MN. Design and implementation of the hospital airway resuscitation trial. Resusc Plus. 2023 Nov 30;17:100512. doi: 10.1016/j.resplu.2023.100512. eCollection 2024 Mar. PubMed 38076388 ↗
  • Fein DG, Zhao D, Swartz K, Nauka P, Andrea L, Aboodi M, Shiloh AL, Eisen LA. The Impact of Nighttime on First Pass Success During the Emergent Endotracheal Intubation of Critically Ill Patients. J Intensive Care Med. 2021 Dec;36(12):1498-1506. doi: 10.1177/0885066620965166. Epub 2020 Oct 15. PubMed 33054483 ↗
  • Nauka PC, Chen JT, Shiloh AL, Eisen LA, Fein DG. Practice, Outcomes, and Complications of Emergent Endotracheal Intubation by Critical Care Practitioners During the COVID-19 Pandemic. Chest. 2021 Dec;160(6):2112-2122. doi: 10.1016/j.chest.2021.06.008. Epub 2021 Jun 15. PubMed 34139207 ↗
  • Janz DR, Semler MW, Lentz RJ, Matthews DT, Assad TR, Norman BC, Keriwala RD, Ferrell BA, Noto MJ, Shaver CM, Richmond BW, Zinggeler Berg J, Rice TW; Facilitating EndotracheaL intubation by Laryngoscopy technique and apneic Oxygenation Within the ICU Investigators and the Pragmatic Critical Care Research Group. Randomized Trial of Video Laryngoscopy for Endotracheal Intubation of Critically Ill Adults. Crit Care Med. 2016 Nov;44(11):1980-1987. doi: 10.1097/CCM.0000000000001841. PubMed 27355526 ↗
  • Driver B, Dodd K, Klein LR, Buckley R, Robinson A, McGill JW, Reardon RF, Prekker ME. The Bougie and First-Pass Success in the Emergency Department. Ann Emerg Med. 2017 Oct;70(4):473-478.e1. doi: 10.1016/j.annemergmed.2017.04.033. PubMed 28601269 ↗
  • Driver BE, Prekker ME, Klein LR, Reardon RF, Miner JR, Fagerstrom ET, Cleghorn MR, McGill JW, Cole JB. Effect of Use of a Bougie vs Endotracheal Tube and Stylet on First-Attempt Intubation Success Among Patients With Difficult Airways Undergoing Emergency Intubation: A Randomized Clinical Trial. JAMA. 2018 Jun 5;319(21):2179-2189. doi: 10.1001/jama.2018.6496. PubMed 29800096 ↗
  • Driver BE, Semler MW, Self WH, Ginde AA, Trent SA, Gandotra S, Smith LM, Page DB, Vonderhaar DJ, West JR, Joffe AM, Mitchell SH, Doerschug KC, Hughes CG, High K, Landsperger JS, Jackson KE, Howell MP, Robison SW, Gaillard JP, Whitson MR, Barnes CM, Latimer AJ, Koppurapu VS, Alvis BD, Russell DW, Gibbs KW, Wang L, Lindsell CJ, Janz DR, Rice TW, Prekker ME, Casey JD; BOUGIE Investigators and the Pragmatic Critical Care Research Group. Effect of Use of a Bougie vs Endotracheal Tube With Stylet on Successful Intubation on the First Attempt Among Critically Ill Patients Undergoing Tracheal Intubation: A Randomized Clinical Trial. JAMA. 2021 Dec 28;326(24):2488-2497. doi: 10.1001/jama.2021.22002. PubMed 34879143 ↗
  • Self WH, Semler MW, Wanderer JP, Ehrenfeld JM, Byrne DW, Wang L, Atchison L, Felbinger M, Jones ID, Russ S, Shaw AD, Bernard GR, Rice TW. Saline versus balanced crystalloids for intravenous fluid therapy in the emergency department: study protocol for a cluster-randomized, multiple-crossover trial. Trials. 2017 Apr 13;18(1):178. doi: 10.1186/s13063-017-1923-6. PubMed 28407811 ↗
  • Semler MW, Self WH, Wanderer JP, Ehrenfeld JM, Wang L, Byrne DW, Stollings JL, Kumar AB, Hughes CG, Hernandez A, Guillamondegui OD, May AK, Weavind L, Casey JD, Siew ED, Shaw AD, Bernard GR, Rice TW; SMART Investigators and the Pragmatic Critical Care Research Group. Balanced Crystalloids versus Saline in Critically Ill Adults. N Engl J Med. 2018 Mar 1;378(9):829-839. doi: 10.1056/NEJMoa1711584. Epub 2018 Feb 27. PubMed 29485925 ↗
  • Gong MN, Schenk L, Gajic O, Mirhaji P, Sloan J, Dong Y, Festic E, Herasevich V. Early intervention of patients at risk for acute respiratory failure and prolonged mechanical ventilation with a checklist aimed at the prevention of organ failure: protocol for a pragmatic stepped-wedged cluster trial of PROOFCheck. BMJ Open. 2016 Jun 10;6(6):e011347. doi: 10.1136/bmjopen-2016-011347. PubMed 27288382 ↗
  • Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010 Mar 23;340:c332. doi: 10.1136/bmj.c332. PubMed 20332509 ↗
  • Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010 Mar 23;340:c869. doi: 10.1136/bmj.c869. No abstract available. PubMed 20332511 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data collected during the trial will be shared through the NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC), in accordance with NHLBI data sharing policy. More detailed data may be made available on request for collaboration, peer review, or other appropriate purposes. All sharing will comply with applicable patient confidentiality regulations. Resource Sharing: Key resources, including methodologies and statistical practices, will be made available in the form of peer-reviewed publications during the trial period. The HART investigators will additionally be open to queries from other investigators regarding elements of the trial.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be available through BioLINCC no later than 3 years after the end of enrollment of the last participant.

Access criteria: Access is through BioLINCC's standard request process. Requests for more detailed data beyond the BioLINCC deposit may be made to the study investigators and will be considered for collaboration, peer review, or other appropriate purposes, subject to confidentiality protections.

Data sharing details ↗ · biolincc.nhlbi.nih.gov

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Aug 2026, 41 months.

Of 205 non-industry interventional studies with no phase under Heart Arrest, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 47. This study's 41 months is above that.

Counting every sponsor, half of 219 studies reached it within 28 months; a quarter within 10 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Jan 2027 → Aug 2026 and completion Feb 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2022
First posted
Aug 30, 2022
StartActual
Feb 10, 2023
Primary completionActual
Aug 3, 2026was Jan 2027
CompletionActual
Sep 3, 2026was Feb 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 20, 2026
Primary completion
Jan 2027→Aug 3, 2026 (actual)
Oct 20, 2026
Study completion
Feb 2027→Sep 3, 2026 (actual)
Oct 20, 2026
Enrollment
1060 (estimated)→1083 (actual)
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Recruiting→Completed
    Primary completion Jan 2027→Aug 3, 2026 (now actual)
    Study completion Feb 2027→Sep 3, 2026 (now actual)
    Enrollment 1060 (estimated)→1083 (actual)
    + 4 other changes: verification date, contact details, site details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05520762
Responsible party
Sponsor
First posted
Aug 30, 2022
Start date
Feb 10, 2023
Primary completion
Aug 3, 2026
Completion
Sep 3, 2026
Last update
Oct 20, 2026

Study contacts

Ari Moskowitz, MD
principal investigator · Montefiore Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion